First-line serplulimab for advanced squamous non-small cell lung cancer: A multicenter, single-arm, real-world ASTRUM 004R study

被引：0
|
作者：
Shen, B. [1 ,2 ,3 ]
Yu, Z. [4 ]
Ding, H. [5 ]
Wang, H. [6 ]
Li, J. [7 ]
Xu, X. [8 ]
Tian, G. [9 ]
Han, G. [10 ]
Yin, L. [11 ]
Ji, Y. [12 ]
Zhou, Z. [13 ]
Zhou, L. [14 ]
Zhang, X. [15 ]
Sun, C. [16 ]
Ding, N. [17 ]
机构：
[1] Nanjing Med Univ, Jiangsu Canc Hosp, Med Oncol Dept, Nanjing, Peoples R China
[2] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Peoples R China
[3] Nanjing Med Univ, Canc Hosp, Nanjing, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China
[5] First Peoples Hosp Zhenjiang, Dept Respirat, Zhenjiang, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China
[7] Wuhu Second Peoples Hosp, Dept Resp Med, Wuhu, Peoples R China
[8] Linyi Peoples Hosp, Dept Resp Med, Linyi, Peoples R China
[9] Jining Med Coll, Affiliated Hosp, Dept Resp Med, Jining, Peoples R China
[10] Taizhou Peoples Hosp, Dept Med Oncol, Taizhou, Peoples R China
[11] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian, Peoples R China
[12] Anyang Canc Hosp, Dept Internal Med, Anyang, South Korea
[13] First Peoples Hosp Yancheng, Dept Respirat, Yancheng, Peoples R China
[14] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Resp Med, Nanjing, Peoples R China
[15] Qingdao Cent Hosp, Dept Stereotact Radiotherapy, Qingdao 266000, Peoples R China
[16] Yangzhou Univ, Canc Inst, Northern Jiangsu Peoples Hosp, Coll Med, Yangzhou 255000, Jiangsu, Peoples R China
[17] Wuxi Huishan Dist Peoples Hosp, Oncol Dept, Wuxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.715
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
682P
引用
收藏
页码：S1660 / S1660
页数：1
相关论文
共 50 条
  • [1] A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (ASTRUM-004)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 7 - 8
  • [2] Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
    Zhou, C.
    Hu, Y.
    Ying, K.
    Xu, F.
    Wu, L.
    Wang, X.
    Sun, H.
    Luo, F.
    Shi, J.
    Zang, A.
    Pan, Y.
    Chen, Z.
    Jia, Z.
    Lu, P.
    Zhang, L.
    Cheng, Y.
    Kang, W.
    Wang, Q.
    Li, J.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1680 - S1680
  • [3] Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study
    Wu, L.
    Hu, C.
    Su, W.
    Yu, Y.
    Hong, W.
    Liu, Z.
    Su, H.
    Liu, Z.
    Wang, C.
    Pu, Q.
    Guo, H.
    Min, X.
    Chen, Y.
    Zhu, H.
    Luo, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S209 - S209
  • [4] A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
    Zhou, Caicun
    Hu, Yanping
    Arkania, Ekaterine
    Kilickap, Saadettin
    Ying, Kejing
    Xu, Fei
    Wu, Lin
    Wang, Xiang
    Viguro, Maksym
    Makharadze, Tamta
    Sun, Hongmei
    Luo, Feng
    Shi, Jianhua
    Zang, Aimin
    Pan, Yueyin
    Chen, Zhendong
    Jia, Zhongyao
    Kuchava, Vladimer
    Lu, Ping
    Zhang, Ling
    Cheng, Ying
    Kang, Wenying
    Wang, Qingyu
    Yu, Haoyu
    Li, Jing
    Zhu, Jun
    CANCER CELL, 2024, 42 (02) : 198 - 208.e3
  • [5] A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)
    Zhou, C.
    Hu, Y.
    Arkania, E.
    Kilickap, S.
    Ying, K.
    Xu, F.
    Wu, L.
    Wang, X.
    Viguro, M.
    Makharadze, T.
    Sun, H.
    Luo, F.
    Shi, J.
    Zang, A.
    Pan, Y.
    Chen, Z.
    Jia, Z.
    Kuchava, V.
    Lu, P.
    Zhang, L.
    Cheng, Y.
    Li, W.
    Kang, W.
    Wang, Q.
    Yang, G.
    Yu, H.
    Li, J.
    Zhu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S63 - S64
  • [6] Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The multicenter ASTRUM-005R study.
    Wu, Lin
    Hu, ChengPing
    Su, Wenzhong
    Yu, Yan
    Hong, Wei
    Liu, Zhigang
    Su, Haichuan
    Liu, Zhentian
    Wang, Caixia
    Pu, Qing
    Guo, Hui, Sr.
    Min, Xuhong
    Chen, Yifei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam
    Pham, C. T. M.
    Truong, M. C.
    Do, T. A.
    Pham, P. C.
    Nguyen, H. T. T.
    Nguyen, K. T.
    Hoang, T. T. A.
    Le, A. T.
    Vuong, H. D. T.
    Nguyen, T. D. N.
    Dang, K. V.
    Nguyen, O. T.
    Luan, P. V.
    Nguyen, H. M.
    Vo, T. T. H.
    Do, K. H.
    Vu, T. H.
    Nguyen, H. T. T.
    Pham, T. V.
    Trinh, H. L.
    Nguyen, G. H.
    Nguyen, P. T. B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S630 - S631
  • [8] Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial
    Xiang, Heng
    Meng, Kehui
    Wu, Meiyu
    Tan, Chongqing
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (08) : 1043 - 1051
  • [9] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C. K.
    Chai, C.
    Ho, G.
    Alip, A.
    Wahid, M. I. A.
    Abdullah, M. M.
    Foo, Y. C.
    How, S. H.
    Zaatar, A.
    Lam, K. S.
    Leong, K. W.
    Low, J. S. H.
    Yusof, M. Md
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
  • [10] A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Liu, Yanxia
    Gao, Yuan
    Wang, Ying
    Zhao, Cong
    Zhang, Zhiyun
    Li, Baolan
    Zhang, Tongmei
    BMC CANCER, 2022, 22 (01)
12345